公开(公告)号：EP0803250B1

公开(公告)日：2002-06-05

申请号：EP96308424.9

申请日：1996-11-21

申请人： AMERICAN HOME PRODUCTS CORPORATION

发明人： Barcomb, Reginald Joseph

IPC分类号： A61K9/20

CPC分类号： A61K31/57 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/209 ,  A61K31/565 ,  A61K31/566 ,  A61K31/567 ,  A61K31/568 ,  A61K31/569 ,  A61K31/575 ,  Y10S514/01 ,  Y10S514/843 ,  Y10S514/899 ,  A61K2300/00

公开(公告)号：EP1159965A3

公开(公告)日：2002-05-22

申请号：EP01117955.3

申请日：1994-02-18

申请人： THE MEDICAL COLLEGE OF HAMPTON ROADS

发明人： Hodgen, Garry D.

IPC分类号： A61K31/565 ,  A61P15/18

CPC分类号： A61K31/565 ,  Y10S514/01 ,  Y10S514/843

摘要： The use of a progesterone receptor antagonist for the preparation of a pharmaceutical composition for preventing an oocyte from becoming fertilized without preventing ovulation or interfering with the regularity of the ovarian menstrual cycle of a mammal.

公开(公告)号：EP0776659B1

公开(公告)日：2002-04-10

申请号：EP96402309.7

申请日：1996-10-30

申请人： Aventis Pharma S.A.

发明人： Nabahi, Shohré

IPC分类号： A61K9/02 ,  A61M31/00 ,  A61K9/20

CPC分类号： A61K9/0036 ,  Y10S514/01

公开(公告)号：EP0642799B1

公开(公告)日：2001-11-07

申请号：EP94113388.6

申请日：1994-08-26

申请人： HOECHST AKTIENGESELLSCHAFT ,  Laboratoires Hoechst Houde S.A.

发明人： Bosslet, Dr. Klaus ,  Czech, Dr. Jörg ,  Hoffmann, Dr. Dieter ,  Tillequin, Prof. François ,  Florent, Dr. Jean-Claude ,  Azoulay, Dr. Michel ,  Monneret, Dr. Claude ,  Jacquesy, Prof. Jean-Claude ,  Gesson, Prof. Jean-Pierre ,  Koch, Prof. Michel ,  Vasella, Prof. Andrea ,  Hoos, Roland

IPC分类号： A61K47/48

CPC分类号： B82Y5/00 ,  A61K47/549 ,  A61K47/6899 ,  Y10S514/01

公开(公告)号：EP0767799A1

公开(公告)日：1997-04-16

申请号：EP95922207.0

申请日：1995-06-05

申请人： PANORAMA RESEARCH, INC.

发明人： WRIGHT, Susan C. ,  LARRICK, James W.

IPC分类号： C12N9 ,  A61K38

CPC分类号： C12N9/6421 ,  A61K38/00 ,  Y10S514/01

摘要： A 24 kilodalton cytoplasmic protease which cleaves at proline-valine bonds is purified from UV-induced human U937 histiocytic lymphoma cells by affinity chromatography using the inhibitor DK120 as the ligand, followed by heparin-sepharose chromatography and reverse phase HPLC. Treating nuclei of uninduced U937 cells with the affinity-purified protease is sufficient to activate internucleosomal DNA fragmentation characteristic of apoptosis as demonstrated by gel electrophoresis in the figure.

公开(公告)号：EP0748217A1

公开(公告)日：1996-12-18

申请号：EP95909451.0

申请日：1995-02-09

申请人： KOS PHARMACEUTICALS, INC.

发明人： THEOHARIDES, Theoharis, C.

IPC分类号： A61K31 ,  A61K38 ,  A61P1

CPC分类号： A61K38/09 ,  A61K31/00 ,  A61K31/13 ,  A61K31/135 ,  A61K31/35 ,  A61K31/415 ,  A61K31/417 ,  A61K31/445 ,  A61K31/495 ,  A61K31/55 ,  A61K31/565 ,  Y10S514/01 ,  A61K2300/00

摘要： A method for treating endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin, such as abdominal migraine and irritable bowel syndrome, entails administering a pharmacologically effective amount of a mast cell degranulation-blocking agent, e.g. a naturally occurring polyamine, a heterocyclic histamine-1 receptor antagonist, a histamine-3 receptor agonist or an anti-female sex hormone.

公开(公告)号：EP0723439A1

公开(公告)日：1996-07-31

申请号：EP94929553.0

申请日：1994-10-17

申请人： SCHERING AKTIENGESELLSCHAFT

发明人： CHWALISZ, Kristof ,  Stöckemann, Klaus

IPC分类号： A61K45 ,  A61K31 ,  A61P9 ,  A61P19 ,  A61P43

CPC分类号： A61K31/565 ,  A61K31/575 ,  Y10S514/01 ,  A61K31/40 ,  A61K31/135 ,  A61K31/445 ,  A61K2300/00

摘要： The application describes the use of at least one compound with progesterone antagonistic (PA) action and at least one compound with anti-oestrogenic (AO) action, together with partial agonistic action, in the preparation of drugs for hormone-replacement therapy (HRT) for peri- and post-menopausal women. When PA and AO are used in combination, the stimulation of the endometrium which is caused by the partial agonistic action of the AO when the AO is used alone is inhibited by the PA. A drug as proposed by the invention could, for instance, contain onapriston (PA) and tamoxifen (AO).

公开(公告)号：EP0712311A1

公开(公告)日：1996-05-22

申请号：EP94924819.0

申请日：1994-07-28

申请人： Akzo Nobel N.V.

发明人： PEETERS, Bernardus Wynand Machijs Marie

IPC分类号： A61K31 ,  A61P25 ,  C07J7

CPC分类号： A61K31/565 ,  Y10S514/01

摘要： The invention relates to the use of antiglucocorticoid steroids for the manufacture of a pharmaceutical composition for the treatment of anxiety disorders.

摘要翻译： 本发明涉及抗糖皮质激素类固醇在制备用于治疗焦虑症的药物组合物中的应用。

公开(公告)号：EP0684825A1

公开(公告)日：1995-12-06

申请号：EP94910707.0

申请日：1994-02-18

申请人： THE MEDICAL COLLEGE OF HAMPTON ROADS

发明人： HODGEN, Gary D.

IPC分类号： A61K31 ,  A61P15 ,  C07J1 ,  A61P5

CPC分类号： A61K31/565 ,  Y10S514/01 ,  Y10S514/843

摘要： Fertilization of an oocyte is prevented or inhibited by administering a fertilizing inhibitory amount of an antiprogestin to an ovulatory mammal in an amount which is insufficient to prevent ovulation but sufficient to inhibit fertilization, while the regularity of the menstrual cycle is sustained.

公开(公告)号：EP0639970A1

公开(公告)日：1995-03-01

申请号：EP93909968.0

申请日：1993-05-12

申请人： SCHERING AKTIENGESELLSCHAFT

发明人： CHWALISZ, Krzysztof ,  SCHMIDT-GOLLWITZER, Karin ,  OTTOW, Eckhard ,  KLAR, Ulrich ,  MICHNA, Horst ,  Elger. Walter, Dr.

IPC分类号： A61K45 ,  A61K31 ,  A61P15 ,  C07J9 ,  C07J43 ,  C07J53

CPC分类号： A61K31/565 ,  A61K31/00 ,  A61K31/57 ,  A61K31/575 ,  A61K31/58 ,  C07J53/002 ,  Y10S514/01 ,  Y10S514/843

摘要： Competitive progesterone antagonists, including two novel steroids, viz., 11β,19-[4-(cyanophenyl)-o-phenylene]-17β-hydroxy-17α-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one and 11β,19-[4-(3-pyridinyl)-o-phenylene]-17β-hydroxy-17α-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one, inhibit formation of endometrial glands at below their ovulation inhibiting dose and the abortive dose, and thus achieve oral contraception in females without adversely affecting the menstrual cycle and without risk of aborting a previous implanted fertilized egg or a fetus.

摘要翻译： 竞争性黄体酮拮抗剂包括两种新的类固醇，即11β，19- [4-（氰基苯基） - 邻 - 亚苯基]-17β-羟基-17α-（3-羟基丙基-1（Z） - 烯基）-4-雄甾烯 -3-酮和11β，19- [4-（3-吡啶基） - 邻 - 亚苯基]-17β-羟基-17α-（3-羟基丙基-1（Z） - 烯基）-4-雄甾-3-酮， 以低于其排卵抑制剂量和流产剂量抑制子宫内膜腺体的形成，从而实现女性的口服避孕，而不会对月经周期产生不利影响，并且没有中断先前植入的受精卵或胎儿的风险。